Literature DB >> 24338353

An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy.

Viktor Dahl1, Magnus Gisslen, Lars Hagberg, Julia Peterson, Wei Shao, Serena Spudich, Richard W Price, Sarah Palmer.   

Abstract

We sequenced the genome of human immunodeficiency virus type 1 (HIV-1) recovered from 70 cerebrospinal fluid (CSF) specimens and 29 plasma samples and corresponding samples obtained before treatment initiation from 17 subjects receiving suppressive therapy. More CSF sequences than plasma sequences were hypermutants. We determined CSF sequences and plasma sequences in specimens obtained from 2 subjects after treatment initiation. In one subject, we found genetically distinct CSF and plasma sequences, indicating that they came from HIV-1 from 2 different compartments, one potentially the central nervous system, during suppressive therapy. In addition, there was little evidence of viral evolution in the CSF during therapy, suggesting that continuous virus replication is not the major cause of viral persistence in the central nervous system.

Entities:  

Keywords:  CNS; CSF; HIV; central nervous system; cerebrospinal fluid; compartmentalization; hypermutants; reservoir; suppressive; therapy

Mesh:

Substances:

Year:  2013        PMID: 24338353      PMCID: PMC3997583          DOI: 10.1093/infdis/jit805

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.

Authors:  Asa Mellgren; Andrea Antinori; Paola Cinque; Richard W Price; Christian Eggers; Lars Hagberg; Magnus Gisslén
Journal:  Antivir Ther       Date:  2005

2.  Central nervous system viral invasion and inflammation during acute HIV infection.

Authors:  Victor Valcour; Thep Chalermchai; Napapon Sailasuta; Mary Marovich; Sukalaya Lerdlum; Duanghathai Suttichom; Nijasri C Suwanwela; Linda Jagodzinski; Nelson Michael; Serena Spudich; Frits van Griensven; Mark de Souza; Jerome Kim; Jintanat Ananworanich
Journal:  J Infect Dis       Date:  2012-05-02       Impact factor: 5.226

3.  Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.

Authors:  Aylin Yilmaz; Chris Verhofstede; Antonio D'Avolio; Victoria Watson; Lars Hagberg; Dietmar Fuchs; Bo Svennerholm; Magnus Gisslén
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12-15       Impact factor: 3.731

4.  Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.

Authors:  Serena Spudich; Magnus Gisslen; Lars Hagberg; Evelyn Lee; Teri Liegler; Bruce Brew; Dietmar Fuchs; Giuseppe Tambussi; Paola Cinque; Frederick M Hecht; Richard W Price
Journal:  J Infect Dis       Date:  2011-09-01       Impact factor: 5.226

5.  Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.

Authors:  Sarah Palmer; Mary Kearney; Frank Maldarelli; Elias K Halvas; Christian J Bixby; Holly Bazmi; Diane Rock; Judith Falloon; Richard T Davey; Robin L Dewar; Julia A Metcalf; Scott Hammer; John W Mellors; John M Coffin
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

6.  Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.

Authors:  Viktor Dahl; Evelyn Lee; Julia Peterson; Serena S Spudich; Idris Leppla; Elizabeth Sinclair; Dietmar Fuchs; Sarah Palmer; Richard W Price
Journal:  J Infect Dis       Date:  2011-10-21       Impact factor: 5.226

Review 7.  Neurologic complications of HIV disease and their treatment.

Authors:  Scott L Letendre; Ronald J Ellis; Beau M Ances; J Allen McCutchan
Journal:  Top HIV Med       Date:  2010 Apr-May

8.  Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection.

Authors:  Gretja Schnell; Richard W Price; Ronald Swanstrom; Serena Spudich
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

9.  Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course.

Authors:  Patrick R Harrington; Gretja Schnell; Scott L Letendre; Kimberly Ritola; Kevin Robertson; Colin Hall; Christina L Burch; Cassandra B Jabara; Dominic T Moore; Ronald J Ellis; Richard W Price; Ronald Swanstrom
Journal:  AIDS       Date:  2009-05-15       Impact factor: 4.177

10.  Central nervous system compartmentalization of HIV-1 subtype C variants early and late in infection in young children.

Authors:  Christa Buckheit Sturdevant; Anna Dow; Cassandra B Jabara; Sarah B Joseph; Gretja Schnell; Nobutoki Takamune; Macpherson Mallewa; Robert S Heyderman; Annelies Van Rie; Ronald Swanstrom
Journal:  PLoS Pathog       Date:  2012-12-27       Impact factor: 6.823

View more
  32 in total

Review 1.  HIV reservoirs: what, where and how to target them.

Authors:  Melissa J Churchill; Steven G Deeks; David M Margolis; Robert F Siliciano; Ronald Swanstrom
Journal:  Nat Rev Microbiol       Date:  2015-11-30       Impact factor: 60.633

2.  Persistence of SIV in the brain of SIV-infected Chinese rhesus macaques with or without antiretroviral therapy.

Authors:  Stefanie Perez; Ann-Marie Johnson; Shi-Hua Xiang; Jian Li; Brian T Foley; Lara Doyle-Meyers; Antonito Panganiban; Amitinder Kaur; Ronald S Veazey; Yuntao Wu; Binhua Ling
Journal:  J Neurovirol       Date:  2017-11-27       Impact factor: 2.643

3.  Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.

Authors:  Viktor Dahl; Julia Peterson; Dietmar Fuchs; Magnus Gisslen; Sarah Palmer; Richard W Price
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

4.  Genetic analyses of HIV env associated with uveitis in antiretroviral-naive individuals.

Authors:  Corey A Williams-Wietzikoski; Isaac D So; Marta E Bull; Tanawan Samleerat; Kessara Pathanapitoon; Paradee Kunavisarut; Natedao Kongyai; Nicole Ngo-Giang-Huong; Lisa M Frenkel; Wasna Sirirungsi
Journal:  AIDS       Date:  2017-08-24       Impact factor: 4.177

Review 5.  Treating HIV Infection in the Central Nervous System.

Authors:  A Calcagno; G Di Perri; S Bonora
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

Review 6.  Advances toward Curing HIV-1 Infection in Tissue Reservoirs.

Authors:  Lisa J Henderson; Lauren B Reoma; Joseph A Kovacs; Avindra Nath
Journal:  J Virol       Date:  2020-01-17       Impact factor: 5.103

7.  HIV Diversity and Genetic Compartmentalization in Blood and Testes during Suppressive Antiretroviral Therapy.

Authors:  Rachel L Miller; Rosalie Ponte; Zabrina L Brumme; Jean-Pierre Routy; Bradley R Jones; Natalie N Kinloch; Fredrick H Omondi; Mohammad-Ali Jenabian; Franck P Dupuy; Remi Fromentin; Pierre Brassard; Vikram Mehraj; Nicolas Chomont; Art F Y Poon; Jeffrey B Joy
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

Review 8.  HIV-1 Reservoirs During Suppressive Therapy.

Authors:  Kirston Barton; Anni Winckelmann; Sarah Palmer
Journal:  Trends Microbiol       Date:  2016-02-12       Impact factor: 17.079

Review 9.  CNS Persistence of HIV-1 in Children: the Untapped Reservoir.

Authors:  Ann Chahroudi; Thor A Wagner; Deborah Persaud
Journal:  Curr HIV/AIDS Rep       Date:  2018-10       Impact factor: 5.071

10.  Drug Resistance Mutation Frequency of Single-Genome Amplification-Derived HIV-1 Polymerase Genomes in the Cerebrospinal Fluid and Plasma of HIV-1-Infected Individuals under Nonsuppressive Therapy.

Authors:  Leslie St Bernard; Jeremy Abolade; Hiroshi Mohri; Martin Markowitz; Teresa H Evering
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.